Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Papillomavirus Infections 1Human Papillomavirus-Related Cervical Carcinoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 2adacel 2Tetanus Toxoid 2Oxaliplatin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diphtheria-Tetanus-acellular Pertussis Vaccines 2Diphtheria Toxoid 2testosterone enanthate 1sofosbuvir-velpatasvir drug combination 1pegfilgrastim 1fluarix 1epoetin beta 1arexvy 1abrysvo 1Vincristine 1Thyrotropin Alfa 1Radiotherapy 1Oxycodone 1Morphine 1Levopropoxyphene 1Leucovorin 1Irinotecan 1Influenza Vaccines 1Heplisav-B 1Fluorouracil 1FluLaval 1Filgrastim 1Etanercept 1Epoetin Alfa 1Dutasteride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × NIH × adacel × Clear all
NCT05237947 2026-05-28

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT03180034 2025-09-04

ESCUDDO

National Cancer Institute (NCI)

Phase 4 Active not recruiting
27,945 enrolled

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡